Contrast-enhanced magnetic resonance imaging of myocardium at risk
Distinction between reversible and irreversible injury throughout infarct healing
David S. Fieno, PhD*  ,
Raymond J. Kim, MD, FACC*  ,
Enn-Ling Chen, PhD*,
Jon W. Lomasney, MD*  ,
Francis J. Klocke, MD, MACC* and
Robert M. Judd, PhD*
* Northwestern University Medical School Feinberg Cardiovascular Research Institute, Chicago, Illinois, USA
Department of Medicine, Chicago, Illinois, USA
Department of Pathology, Chicago, Illinois, USA
Department of Biomedical Engineering, Chicago, Illinois, USA
View larger version (94K):
[in a new window]
|
Figure 1 Hyperenhancement was observed at 1 day, 3 days, 10 days, 4 weeks and 8 weeks after nonreperfused (top row) and reperfused (bottom row) myocardial infarction.
|
|
View larger version (95K):
[in a new window]
|
Figure 2 Hyperenhancement observed in vivo was similar to that observed ex vivo.
|
|
View larger version (75K):
[in a new window]
|
Figure 3 The size and shape of hyperenhanced regions by MRI closely matched those of irreversible injury defined by TTC throughout infarct healing.
|
|
View larger version (47K):
[in a new window]
|
Figure 4 The size and shape of regions with reduced perfusion ("at risk") were larger than the hyperenhanced areas by ceMRI.
|
|
View larger version (125K):
[in a new window]
|
Figure 5 Comparison of MRI hyperenhancement (left upper panel), TTC staining (left middle panel) and the myocardium at risk (region without fluorescent microparticles, left lower panel) in an animal with a 1-day-old reperfused infarction. Light microscopy views of region 1 (not at risk, not infarcted), region 2 (at risk but not infarcted) and region 3 (infarcted) are shown on the right panels. Arrows point to contraction bands. See text for details.
|
|
View larger version (19K):
[in a new window]
|
Figure 6 Hyperenhancement was not observed in "at risk but not infarcted" regions.
|
|
|
